Haleon (HLN) Stock

Haleon plc is showing strong organic growth, mainly due to its strong oral health brands like Sensodyne and Parodontax. This growth continues even with some challenging comparisons in the results, especially in the VMS sector. The company expects organic growth to stay around 4-6%, not taking into account foreign exchange impacts, despite the positive trends seen in the third quarter.

WARREN, N.J., Dec. 2, 2024 /PRNewswire/ -- Haleon, a top global consumer health company, is happy to share that Joe Sta-Romana has been named Chief Customer Officer (CCO) for its US operations, starting December 1, 2024.

Vistar Media's programmatic out-of-home technology will improve Haleon's high-quality global media approach. This technology aims to boost Haleon's advertising strategy on a worldwide scale.

Haleon plc (NYSE:HLN) will hold a sales conference call for the third quarter of 2024 on October 31, 2024, at 5:00 AM ET. The call will feature Rakesh Patel, the Director of Investor Relations, and Tobias Hestler, the Chief Financial Officer. Various participants from major financial institutions will also be joining the call.

Due to changes in currency values, Haleon PLC, the company behind Panadol and Sensodyne, reported a 0.6% decrease in revenue to £2.78 billion in the third quarter compared to last year. However, if we exclude the effects of the weaker US dollar, the company's organic revenues actually grew by 6.1%.

On Thursday, Haleon announced a slight decrease in its revenue for the third quarter, affected by lower sales in its pain relief and digestive health areas.

Futura Medical PLC (AIM:FUM, OTC:FAMDF) has received a $5 million milestone payment after launching its main product, Eroxon, in the US. This payment was activated when Haleon, the company's distribution partner, started processing online pre-orders and made the quick-acting erectile dysfunction gel available in US retail shops.

UBS has confirmed its buy rating for Haleon PLC shares following the announcement that Pfizer Inc has reduced its stake in the company. Haleon, which includes the former consumer divisions of Pfizer and GSK, has decided to buy back about £230 million of its own shares after Pfizer announced it was selling off around £2.1 billion of its shares.

Haleon PLC (LSE:HLN, NYSE:HLN) announced that it will buy back £230 million worth of its shares from Pfizer Inc (NYSE:PFE, ETR:PFE), which recently sold nearly a $3.3 billion stake in the company that produces Sensodyne. The FTSE 100 consumer health firm stated that the shares were bought at a price of 308p each.